ZLAB News and Press, Zai Lab Limited From 08/10/22

The following slide deck was published by Zai Lab Limited in conjunction with their 2022 Q2 earnings call. For further details see: Zai Lab Limited 2022 Q2 - Results - Earnings Call Presentation

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...

Zai Lab press release ( NASDAQ: ZLAB ): Q2 GAAP EPS of -$0.14 beats by $0.92 . Revenue of $48.17M (+30.4% Y/Y) beats by $1.04M . For further details see: Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M

Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by ZEJULA; strong balance sheet with a cash position of $1.26 billion ...

The shares of Karuna Therapeutics ( NASDAQ: KRTX ) surged ~52% in the pre-market on Monday after the clinical-stage biotech announced that its late-stage trial for experimental schizophrenia therapy KarXT met the primary endpoint. The ADRs of Chinese biotech Zai Lab Limited ...

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative...

Qiming's Portfolio Company InventisBio Lists on STAR Market PR Newswire SHANGHAI , July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the S...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates ...

Inclusion of Zai Lab shares in Shanghai-Hong Kong Stock Connect is effective today Zai Lab has been dual-primary listed on Nasdaq and the Hong Kong Stock Exchange, and its shares included in the Shenzhen-Hong Kong Stock Connect since June 2022 Zai Lab’s incl...

Zai Lab ( NASDAQ: ZLAB ) on Wednesday said China's drug regulator had accepted the company's biologics license application (BLA) for efgartigimod alfa injection for the treatment of generalized myasthenia gravis (gMG). Myasthenia gravis is a disorder characterized by w...